Zometa® contains zoledronic acid, a bisphosphonic acid which is an inhibitor of osteoclastic bone resorption.
Zometa® (zoledronic acid) Injection is indicated for the treatment of hypercalcemia of malignancy.
Vigorous saline hydration, an integral part of hypercalcemia therapy, should be initiated promptly and an attempt should be made to restore the urine output to about 2 L/day throughout treatment. Mild or asymptomatic hypercalcemia may be treated with conservative measures (i.e., saline hydration, with or without loop diuretics). Patients should be hydrated adequately throughout the treatment, but overhydration, especially in those patients who have cardiac failure, must be avoided. Diuretic therapy should not be employed prior to correction of hypovolemia. The safety and efficacy of Zometa in the treatment of hypercalcemia associated with hyperparathyroidism or with other non-tumor-related conditions has not been established.
Zometa is indicated for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy.
Media Articles Related to Zometa (Zoledronic Acid)
Less frequent dosing of drug for patients with bone metastases does not increase risk of fracture, other bone-related events
Source: Bones / Orthopedics News From Medical News Today [2017.01.05]
Among patients with bone metastases due to breast cancer, prostate cancer, or multiple myeloma, use of the bisphosphonate drug zoledronic acid every 12 weeks compared with the standard dosing...
Published Studies Related to Zometa (Zoledronic Acid)
Delaying skeletal-related events in a randomized phase 3 study of denosumab
versus zoledronic acid in patients with advanced cancer: an analysis of data from
patients with solid tumors. 
myeloma... CONCLUSIONS: Denosumab was more effective in delaying or preventing SREs in
Reduction in the risk of clinical fractures after a single dose of zoledronic
Acid 5 milligrams. 
1 infusion of zoledronic acid... CONCLUSIONS: In this post hoc analysis based on postrandomization subgroups,
Clinical significance of zoledronic acid and strontium-89 in patients with
asymptomatic bone metastases from non-small-cell lung cancer. 
lung cancer (NSCLC) with asymptomatic bone metastases (BMs)... CONCLUSIONS: Treatment with ZA and/or Sr-89 significantly extended the time to
Fracture risk and zoledronic acid therapy in men with osteoporosis. 
osteoporosis... CONCLUSIONS: Zoledronic acid treatment was associated with a significantly
Superiority of denosumab to zoledronic acid for prevention of skeletal-related
events: a combined analysis of 3 pivotal, randomised, phase 3 trials. 
across three pivotal studies... CONCLUSION: Denosumab was superior to zoledronic acid in preventing SRE with
Clinical Trials Related to Zometa (Zoledronic Acid)
PET Scanning to Evaluate Zoledronate Efficacy in Metastatic Prostate Cancer [Active, not recruiting]
The primary goal for this trial is to assess the change in PET scans with the administration
of zoledronate (bisphosphonate) therapy in patients with metastatic prostate cancer. It
has been established that zoledronate therapy may play a role in delaying and reducing the
incidence of skeletal events. Researchers propose to evaluate the change in the uptake
value of FMAU PET scan after the zoledronate therapy. It has been demonstrated that FMAU
PET scans can successfully demonstrate and detect bony metastatic sites in prostate cancer.
In addition, investigators would like to evaluate the change in the level of the
prostate-specific antigen (PSA) in the patient as well as outcome of bone scans.
Zometa and Circulating Vascular Endothelial Growth Factor (VEGF) in Breast Cancer Patients With Bone Metastasis [Completed]
The primary objective of this study is to evaluate the effects of Zometa (zoledronic acid, 1
mg per week versus 4 mg every four weeks) on the circulating vascular endothelial growth
factor (VEGF) levels in breast cancer patients with bone metastases. Sixty patients will be
randomized into two groups.
Evaluation of Chemotherapy Prior to Surgery With or Without Zometa for Women With Locally Advanced Breast Cancer [Completed]
This study is designed to evaluate the impact of Zometa on clearance of bone marrow
micrometastases; the protective effect on chemotherapy-induced loss of bone mineral density;
and quality of life in women undergoing treatment for locally advanced breast cancer.
Zometa on Bone Mineral Density in Prostate Cancer Patients Undergoing Androgen Ablation Therapy [Completed]
The purpose of this research is to determine the effect of timing of ZometaŽ administration
on bone mineral density of the lumbar spine and femoral neck in men undergoing androgen
deprivation therapy for prostate adenocarcinoma. In addition, the researchers will also
determine the effects of treatment with ZometaŽ on peripheral blood markers of bone
turnover, on peripheral blood gd T-cell frequencies and function, and to determine if the
above treatments elicit prostate antigen-specific IgG immune responses. The effects of the
above treatments on serial serum PSA measurements will also be examined.
Zometa Adjuvant Treatment of Malignant Pleural Effusion Due To Non-Small Cell Lung Cancer [Terminated]
The purpose of this study is to evaluate whether the addition of the bisphosphonate Zometa
(zoledronic acid) used along with standard regimens of chemotherapy, will help to control
the need for palliative intervention of malignant pleural effusions due to non-small cell
Reports of Suspected Zometa (Zoledronic Acid) Side Effects
Osteonecrosis of JAW (3063),
Back Pain (1223),
Exposed Bone in JAW (1084),
Neoplasm Malignant (1029), more >>
Page last updated: 2017-01-05